BRIEF-Xencor enteres into collaboration and license agreement with Novartis

June 28 Xencor Inc :* Xencor announces strategic collaboration for bispecific programs, including XMAB 14045 and XMAB 13676* Has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics* Parties will collaborate and share development costs for worldwide development of XMAB14045 and XMAB13676, with Xencor * Will receive a $150 million upfront payment and is eligible to receive clinical, regulatory and sales milestone payments for successful programs* Says eligible to receive tiered, low double-digit royalties for sales of XMAB14045 and XMAB13676 outside of U.S. * Novartis to receive worldwide rights to co's bispecific technology to develop and commercialize four additional targets selected by Novartis * Says Novartis will receive a worldwide non-exclusive license to use Xencor's XMAB FC technologies in up to ten moleculesSource text for Eikon:Further company coverage: